| Date | Title | | | 09/07/10 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO, Sep 07, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:
The Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010, at 12:30 p.m. Eastern Time at The New York Palace Hotel in New York City.
... |
|  | | 08/09/10 | ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results| SAN DIEGO, Aug 09, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the second quarter
ended June 30, 2010.
ACADIA reported a net loss of $4.3 million, or $0.11 per common share,
for the second quarter of 2010 compared to... |
| | | 08/02/10 | ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial
Results on August 9, 2010| ACADIA to Host Conference Call and Webcast on Monday, August 9, 2010,
at 5:00 p.m. Eastern Time
SAN DIEGO, Aug 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 2010... |
| | | 07/29/10 | ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial
with Pimavanserin for Parkinson's Disease Psychosis| SAN DIEGO, Jul 29, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has initiated a new Phase III trial designed to
evaluate the efficacy, tolerability and safety of pimavanserin as a
treatment for patients with Parkinson's disease psychosis (PDP).
... |
| | | 06/02/10 | ACADIA Pharmaceuticals To Present at the Ninth Annual Needham
Healthcare Conference on June 9, 2010| SAN DIEGO, Jun 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Ninth Annual Needham
Healthcare Conference on Wednesday, June 9, 2010 at 3:20 p.m. Eastern
Time at The New York Palace Hotel in New York City.
A live webcast of A... |
| | | 05/10/10 | ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results| SAN DIEGO, May 10, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2010.
ACADIA reported a net loss of $5.5 million, or $0.14 per common share,
for the first quarter of 2010 compared to a... |
| | | 05/05/10 | ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities
Research Conference on May 12, 2010| SAN DIEGO, May 05, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Ninth Annual JMP Securities
Research Conference on Wednesday, May 12, 2010 at 11:00 a.m. Pacific
Time at The Ritz-Carlton Hotel in San Francisco.
A live webcast o... |
| | | 05/03/10 | ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial
Results on May 10, 2010| ACADIA to Host Conference Call and Webcast on Monday, May 10, 2010,
at 5:00 p.m. Eastern Time
SAN DIEGO, May 03, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2010 ... |
| | | 04/14/10 | Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting| SAN DIEGO, Apr 14, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Joseph H. Friedman, MD, will present data from ACADIA's previously reported Phase III trial (the -012 Study) with pimavanserin for Parkinson's disease psychosis (PDP) at the 62nd American Academy of Neurology Annual Meeting on ... |
| | | 03/09/10 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth
Quarter and Year Ended December 31, 2009| SAN DIEGO, Mar 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its financial results for the fourth quarter and year
ended December 31, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the fourth quarter of 2009 compared t... |
| | | 03/02/10 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009
Financial Results on March 9, 2010| ACADIA to Host Conference Call and Webcast on Tuesday, March 9, 2010, at 5:00 p.m. Eastern TimeSAN DIEGO, Mar 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended December 31, 2... |
| | | 02/01/10 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010| SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2010 on Monday, February 8, 2010, at 3:00 p.m. Eastern Time
at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACA... |
| |
|
